MD Biosciences Blog

Microbiome Impact on Disease: Translational Microbiome Conference

Posted by MD Biosciences on May 6, 2016 8:15:25 AM

The 2016 Arrowhead Translation Microbiome brought the who’s who of the microbiome community together last week in the heart of Boston. Top key opinion leaders in the field came together to discuss new therapeutic discoveries, disease indications and regulatory pathways. Seres Therapeutics, the leader in microbiome therapy development, opened the meeting discussing their pipeline and recently designated “FDA Breakthrough Therapy”, Ser-109, for the treatment of reoccurring C. difficile infections. Other big players in attendance were Commense and Osel, Inc, who are both working to understand the impact of the vaginal microbiome on health and disease and how to treat a dysbiotic vaginal environment.

Read More

Topics: Microbiome, translational

What is the Impact of Vendor Animal Microbiomes on Disease?

Posted by MD Biosciences on Apr 22, 2016 2:35:00 PM

On Thusday, MD Biosciences' Lead Scientist Britnie James, Ph.D. presented at the 2nd Annual Translational Microbiome Conference held in Boston, MA.  Her talk entitled "Understanding the Impact of Animal Vendors and the Microbiome in Tumor Progression and Treatment in a Model of Metastatic Breast Cancer" highlights the importance of the role of the micorbiome in disease progression and treatment. 

Read More

Topics: Inflammation, cancer/tumor, Microbiome

2015 Recap|Clinical Diagnostics & Translational Research

Posted by MD Biosciences on Dec 17, 2015 4:57:36 PM

As we wind down to years end, we at MD Biosciences would like to thank everyone, especially our collaborators, for making this year a success. We have undergone significant growth that we expect to continue throughout the upcoming year.

Read More

Topics: Pain, Inflammation, Neuro/CNS, post-operative pain, cancer/tumor, Microbiome, Biomarkers, CLIA, Neuropathy

Biomarkers Put Precision In Precision Medicine | AMP 2015

Posted by MD Biosciences on Nov 12, 2015 12:58:51 PM

The 2015 annual AMP meeting opened Novemeber 5th in Austin TX, with a presentation by Dr Brian Druker titled “Imatinib as a Paradigm of Targeted Cancer Therapies.”  This year’s recipient of the AMP Award for Excellence in Molecular Diagnostics, Dr Druker highlighted the importance of identifying patients through biomarkers and matching therapies to the patient.  This theme continued through many of the presentations, posters and vendor exhibits the importance of providing physicians actionable results for patient care and therapeutics.  Molecular diagnostics are critical to any discussion on precision or personalized medicine. 

Read More

Topics: cancer/tumor, Microbiome, Biomarkers, Association for Molecular Pathology, Pathology, precision medicine

Targeting Microbiomes & Biomarkers: Inflammation World Congress

Posted by MD Biosciences on Aug 20, 2015 3:30:00 PM


The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.

Read More

Topics: Inflammation, metabolic, Preclinical Discovery, Microbiome, Biomarkers, World Congress on Inflammation